Zobrazeno 1 - 10
of 111
pro vyhledávání: '"Duncan Wheatley"'
Autor:
Serena Di Cosimo, José Manuel Pérez-García, Meritxell Bellet, Florence Dalenc, Miguel J. Gil Gil, Manuel Ruiz-Borrego, Joaquín Gavilá, Elena Aguirre, Peter Schmid, Frederik Marmé, Joseph Gligorov, Andreas Schneeweiss, Joan Albanell, Pilar Zamora, Duncan Wheatley, Eduardo Martínez de Dueñas, Kepa Amillano, Eileen Shimizu, Miguel Sampayo-Cordero, Javier Cortés, Antonio Llombart-Cussac
Publikováno v:
Breast, Vol 76, Iss , Pp 103761- (2024)
Background: The capsule formulation of CDK4/6 inhibitor palbociclib has reduced solubility at gastric pH > 4.5 and may have decreased activity when used with proton-pump inhibitors (PPI). Herein, we report the effect of PPI on palbociclib capsule act
Externí odkaz:
https://doaj.org/article/d3b96315025744e9a531e42906d8d57a
Autor:
Amit Bahl, William Wilson, Jessica Ball, Emily Renninson, Sidharth Dubey, Alicia Bravo, Emily Foulstone, Saiqa Spensley, Rebecca Bowen, Janine Mansi, Simon Waters, Pippa Riddle, Duncan Wheatley, Peter Stephens, Pavel Bezecny, Srinivasan Madhusudan, Mark Verrill, Jeremy Braybrooke, Charles Comins, Vivek Mohan, Abigail Gee, Hannah Kirk, Alison Markham, Heidi Evans, Eve Watson, Mark Callaway, Sylvia Pearson, Allan Hackshaw, Mark Churn
Publikováno v:
Breast, Vol 66, Iss , Pp 69-76 (2022)
Background: Paclitaxel is commonly used as first-line chemotherapy for HER2-negative metastatic breast cancer (MBC) patients. However, with response rates of 21.5–53.7% and significant risk of peripheral neuropathy, there is need for better chemoth
Externí odkaz:
https://doaj.org/article/82333b9202654f2ab93e6857aabae51e
Autor:
Patrick Neven, Nicole Stahl, Maria Vidal, Miguel Martín, Nadia Harbeck, Peter A. Kaufman, Francois-Clement Bidard, Peter A. Fasching, Philippe Aftimos, Erika Hamilton, Stacey Carter, Peter Schmid, Duncan Wheatley, Manali Bhave, Kelly K. Hunt, Swati A. Kulkarni, Roohi Ismail-Khan, Claudia Karacsonyi, Shawn T. Estrem, Umut Ozbek, Bastien Nguyen, Eva Ciruelos
Publikováno v:
Cancer Research. 83:P6-10
Background: Imlunestrant is a novel, orally bioavailable selective estrogen receptor degrader (SERD) with pure antagonistic properties that result in sustained inhibition of estrogen receptor (ER)-dependent gene transcription and cell growth. In a ph
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c184e561708d681fe7d140c24cd56f0f
https://doi.org/10.1158/1538-7445.sabcs22-p6-10-06
https://doi.org/10.1158/1538-7445.sabcs22-p6-10-06
Autor:
Hamza A. Arabiyat, Iain Brown, Philip Drew, Rachel English, Mona Sulieman, Imran Abbas, Duncan Wheatley, Kali Potiszil, Alastair Thomson, Polly King
Publikováno v:
Cancer Research. 83:P1-10
Introduction: Axillary lymph node dissection (ALND) is associated with significant morbidity. Randomised data [1,2] suggest that axillary radiotherapy (RT), or no further axillary treatment beyond sentinel node biopsy (SNB) may be safe. There are ver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e402a30fa7fd215752b808e648a5353f
https://doi.org/10.1158/1538-7445.sabcs22-p1-10-17
https://doi.org/10.1158/1538-7445.sabcs22-p1-10-17
Autor:
Amit Goyal, Sophie Nicholls, Andrea Marshall, Natalie Hammonds, Duncan Wheatley, Beatrix Elsberger, Janice Rose, Helen-Teresa Edwards, Roeum Butt, Abeer Shaaban, Shama Puri, Samreen Ahmed, Tara Homer, Luke Vale, Julie Bruce, Sophie J. Gasson, Helen Higgins, Janet A. Dunn
Publikováno v:
Cancer Research. 83:OT1-09
Background: For patients who are node positive at presentation and are found to have a complete nodal tumour response (ypN0) post-neoadjuvant chemotherapy (NACT), we do not yet know whether local axillary therapy can be modified based on the response
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::feecd0043f694b5f1f466879074deae0
https://doi.org/10.1158/1538-7445.sabcs22-ot1-09-02
https://doi.org/10.1158/1538-7445.sabcs22-ot1-09-02
Autor:
Hideyuki Akaza, Giuseppe Procopio, Choosak Pripatnanont, Gaetano Facchini, Sergio Fava, Duncan Wheatley, Kwong Chuen Leung, Mohammad Butt, Alberto Silva, Liliana Castillo, Vasilios Karavasilis, Ayse Ӧzatılgan, Simon Hitier, Evelyne B. Ecstein-Fraisse, Mustafa Ӧzgüroḡlu
Publikováno v:
Journal of Global Oncology, Vol 4, Pp 1-12 (2018)
Purpose: There is a major clinical need to devise an optimal treatment sequence for the multiple therapy options available for patients with metastatic castration-resistant prostate cancer (mCRPC). In the absence of prospective clinical trials, seque
Externí odkaz:
https://doaj.org/article/898f38cc5b28407989d12bf6153544a3
Publikováno v:
Cancer Research. 82:P4-07
RationaleNeoadjuvant chemotherapy (NAC) for the treatment of early and locally advanced breast cancer is shown to cause effective tumour shrinkage, allowing breast conserving surgery. However, rates of recurrence remain high following surgical excisi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4247fab762acf228da50893da2e0c43b
https://doi.org/10.1158/1538-7445.sabcs21-p4-07-28
https://doi.org/10.1158/1538-7445.sabcs21-p4-07-28
Autor:
Amit Goyal, Sophie Cramp, Andrea Marshall, Duncan Wheatley, Natalie Hammonds, Shama Puri, Tara Homer, Luke Vale, Roeum Butt, Romaana Mir, Janice Rose, Helen Teresa Edwards, Samreen Ahmed, Abeer Shaaban, Beatrix Elsberger, Julie Bruce, Sophie Gasson, Valerie Speirs, Jacqui Shaw, Helen Higgins, Janet Dunn
Publikováno v:
Cancer Research. 82:OT1-04
Background: For patients who are node positive to start at presentation and are found to have a complete nodal tumour response (ypN0) post neoadjuvant chemotherapy (NACT), we do not yet know whether local axillary therapy can be modified based on the
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb69393a4e9da940b5b1efbe9f9b98d9
https://doi.org/10.1158/1538-7445.sabcs21-ot1-04-01
https://doi.org/10.1158/1538-7445.sabcs21-ot1-04-01
Autor:
Nicholas Turner, Claire Swift, Ben Jenkins, Lucy Kilburn, Maria Coakley, Matthew Beaney, Lisa Fox, Katie Goddard, Isaac Garcia-Murillas, Peter Hall, Catherine Harper-Wynne, Tamas Hickish, Sarah Kernaghan, Iain Macpherson, Alicia Okines, Carlo Palmieri, Sophie Perry, Katrina Randle, Claire Snowdon, Hilary Stobart, Andrew Wardley, Duncan Wheatley, Simon Waters, Matthew Winter, Judith Bliss
Publikováno v:
Cancer Research. 82:GS3-06
Background Detection of circulating tumour DNA (ctDNA) in patients (pts) who have completed treatment for early-stage triple negative breast cancer (TNBC) is associated with a very high risk of future relapse. Identifiying those at high risk of subse
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c87025dfbe68a40c7a5f74097df5e6c8
https://doi.org/10.1158/1538-7445.sabcs21-gs3-06
https://doi.org/10.1158/1538-7445.sabcs21-gs3-06
Autor:
Iain Macpherson, Stuart McIntosh, Lucy Kilburn, Holly Tovey, Sarah Kernaghan, Katie Goddard, Indrani Bhattacharya, Clinton Boyd, Charlotte Coles, Cliona Kirwan, Mairead Mackenzie, Ciara O’Brien, Alistair Ring, Claire Snowdon, Hilary Stobart, Duncan Wheatley, Andrew Wardley, Abeer Shaaban, Peter Hall, David Cameron, Judith Bliss
Publikováno v:
Cancer Research. 82:OT2-05
Background The presence or absence of residual disease following neoadjuvant systemic anti-cancer therapy (neoSACT) for HER2-positive early breast cancer (HER2+ EBC) provides powerful prognostic information that may guide subsequent adjuvant treatmen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a21cd1f2ba7e31cfd59954e7383a662
https://doi.org/10.1158/1538-7445.sabcs21-ot2-05-01
https://doi.org/10.1158/1538-7445.sabcs21-ot2-05-01